• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

$1.5b in cost cutting means layoffs

















It's rolling layoffs. Been happening since last year.

Welcome to BMS. Where execs get $20 million bonuses and the peons are left to worry about whether they can put food on the table for their families.
 




It's rolling layoffs. Been happening since last year.

Welcome to BMS. Where execs get $20 million bonuses and the peons are left to worry about whether they can put food on the table for their families.
Mediocre hiring at the exec level. Shocked that such hires are even considered. This is probably due to the mediocre C suite who keep filling their pockets and need idiots reporting to them who will not question anything.
 




































BMS Kool-Aid drinkers out in full force praying, hoping that their Corporate Masters are being honest with them about future layoffs.

You can't trust a damn thing anyone in this place tells you. Lies and more lies.

This only gets worse from here and I don't plan to stick around to see the inevitable ugly ending.
 




BMS doesn't create medicines and can't manufacture their way out of a box. The current c-suite & board made all of the bad decisions in the last eight to 10 years. So what's left?